Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2010

01-03-2010 | Breast Oncology

Node Micrometastases Detection After Neoadjuvant Chemotherapy in Breast Cancer: Is It of Clinical Value?

Authors: Dimosthenis Ziogas, MD, Haralampos Harissis, MD, Charalabos Batsis, MD

Published in: Annals of Surgical Oncology | Issue 3/2010

Login to get access

Excerpt

It is thought that detection of micrometastases (mi) or isolated tumor cells (ITCs) in sentinel lymph node biopsy (SLNB) or axillary lymph nodes (ALNs) in breast cancer can have prognostic and predictive clinical utility. The American Joint Committee on Cancer (AJCC) recommends lymph node classification into: pN0 (no metastases > 2 mm), pN1mi (small metastases > 0.2 mm to < 2 mm) and pN0(i +) (ITC deposits < 0.2 mm). However, nobody knows whether detection of mi or ITCs in SNLB should be followed by axillary lymph node dissection (ALND) or if this identification of minimal disease in SLNB or ALNs is a predictive marker for response to adjuvant chemotherapy offering a survival benefit. Even more complicated is the topic of detection of mi or ITCs in ALNs after neoadjuvant chemotherapy (NAC). However, even if mi or ITCs detection has prognostic value, what is the clinical utility given that NAC has been completed? …
Literature
1.
go back to reference Sakakibara M, Nagashima T, Kadowaki M, et al. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol. 2009;16(9):2470–8.CrossRefPubMed Sakakibara M, Nagashima T, Kadowaki M, et al. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol. 2009;16(9):2470–8.CrossRefPubMed
2.
go back to reference Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.CrossRefPubMed Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.CrossRefPubMed
3.
go back to reference Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.CrossRefPubMed Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.CrossRefPubMed
5.
go back to reference Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.CrossRefPubMed Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.CrossRefPubMed
6.
go back to reference Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9(3):227–9.CrossRefPubMed Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9(3):227–9.CrossRefPubMed
7.
go back to reference Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9(3):217–21.CrossRefPubMed Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9(3):217–21.CrossRefPubMed
8.
go back to reference Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol. 2009;16(10):2678–81.CrossRefPubMed Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol. 2009;16(10):2678–81.CrossRefPubMed
9.
go back to reference Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.CrossRefPubMed Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.CrossRefPubMed
Metadata
Title
Node Micrometastases Detection After Neoadjuvant Chemotherapy in Breast Cancer: Is It of Clinical Value?
Authors
Dimosthenis Ziogas, MD
Haralampos Harissis, MD
Charalabos Batsis, MD
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0746-4

Other articles of this Issue 3/2010

Annals of Surgical Oncology 3/2010 Go to the issue